Joseph Stringer, an analyst from Needham, reiterated the Buy rating on Gilead Sciences. The associated price target remains the same with $133.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Stringer has given his Buy rating due to a combination of factors that highlight Gilead Sciences’ strong financial performance and growth potential. The company reported robust earnings for the third quarter of 2025, with product sales excluding Veklury reaching $7.07 billion, which aligns with both the firm’s and consensus estimates. This performance was primarily driven by the high demand in their core HIV franchise, particularly through products like Biktarvy and Descovy, and to a lesser extent, their Liver Disease segment.
Additionally, Gilead’s non-GAAP earnings per share exceeded expectations, coming in at $2.47 compared to the anticipated $2.05 and $2.13 by the firm and consensus, respectively. The company also raised its total product sales guidance for 2025, reflecting confidence in continued revenue growth, especially in the HIV sector. Upcoming developments in their HIV treatment program and potential advancements in multiple myeloma treatments are seen as significant catalysts that could further enhance the stock’s performance, supporting the Buy rating and a price target of $133.
Stringer covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Gilead Sciences, and Avidity Biosciences. According to TipRanks, Stringer has an average return of 18.8% and a 46.09% success rate on recommended stocks.
In another report released today, Wells Fargo also maintained a Buy rating on the stock with a $145.00 price target.